PROLIFERATIVE ADVANTAGE RATHER THAN CLASSICAL DRUG-RESISTANCE AS THE CAUSE OF TREATMENT FAILURE IN CHRONIC MYELOGENOUS LEUKEMIA

被引：6

作者：

PREISLER, HD

RAZA, A

BACCARANI, M

机构：

[1] Division of Hematology/Oncology, Rush Cancer Institute, Rush Presbyterian-St. Luke's Medical Center, Chicago

[2] Chair of Hematology, Udine University School of Medicine, Udine

来源：

LEUKEMIA & LYMPHOMA | 1993年 / 11卷

关键词：

CHRONIC MYELOID LEUKEMIA; BLASTIC METAMORPHOSIS;

D O I：

10.3109/10428199309047903

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This presentation discusses the role that proliferative advantage plays in making both the chronic and blastic phases of CML resistant to therapy. A case is made for the addition of ''regrowth'' inhibitors between courses of chemotherapy as a means of increasing the efficacy of therapy by suppressing or reducing the proliferative advantage that the target cells enjoy over those cells which one would like to repopulate the hematopoietic system.

引用

页码：303 / 306

页数：4

共 20 条

[11]

Gopal V., Kadam P., Preisler H.D., Et al., Abnormal regulation of the myc gene in myeloid leukemia, Leukemia

[12]

Wang Z., Gao X.Z., Preisler H.D., Studies of the proliferation and differentiation of immature myeloid cells in vitro: 1) chronic myelogenous leukemia, Am. J. Hematol., 30, pp. 77-82, (1989)

[13]

Preisler H.D., Gopal V., Banavali S., Et al., Multiparameter assessment of the cell cycle effects of bioactive and cytotoxic agents, Cancer Res., 52, pp. 1-7, (1992)

[14]

Banavali S., Pancoast J., Tricot G., Et al., Serial studies of Cmyc expression in bone marrow biopsies: Effects of cytotoxic agents, rhGM-CSF, and retinoic acid, and Interferon

[15]

Preisler H.D., Raza A., Alteration of the proliferative rate of acute myelogenous leukemia cells in vivo in patients, Blood

[16]

Yin M., Gopal V., Banainli S.O., Et al., Effects of an IL-1β receptor antagonist in acute myeloid leukemia cells, Leukemia

[17]

Essner R., Rhondes K., McBride W.H., Et al., IL-4 down-regulates IL-4 and TNF gene expression in human monocytes, J. Immunol., 11, pp. 3857-3861, (1989)

[18]

Donnelly R.P., Fenton M.J., Finbloom D.S., Et al., Differential regulation of IL-1 production in human monocytes by IFN-t and IL-4, J. Immunol., 145, pp. 569-575, (1990)

[19]

Tura S., Et al., A clinical trial of early splenectomy, hydroxyurea, and cyclic cytosine arabinoside, vincristine, and prednisone in chronic myeloid leukemia. Italian Cooperative Study Group in Chronic myeloid leukemia, Ser. Hematol., 8, pp. 121-125, (1975)

[20]

Cunningham I., Gee T., Dowling M., Chagenti R., Et al., Results of treatment of Ph't chronic myelogenous leukemia with an intensive treatment regimen (L-5 protocol), Blood, 53, 3, pp. 375-395, (1979)

← 1 2 →